Trial Profile
Clinical study of enzalutamide on castration resistant prostate cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 12 May 2023 Results investigating the relationship between the serum testosterone (T) level before ENZ treatment and QoL changes in CRPC patients, published in the Prostate
- 19 Feb 2022 Results investigating the relationship between serum testosterone (T) levels before ENZ and QOL changes in CRPC patients, presented at the 2022 Genitourinary Cancers Symposium
- 13 Sep 2021 Results of an analysis assessing the the relationship between the efficacy of Enzalutamide on castration resistant prostate cancer and serum androgen concentrations before administration presented at the 116th Annual Meeting of the American Urological Association